The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

SureCN56060     (4R,5R,6S)-3-[(3S,5S)-5...

Synonyms: Merrem (TN), CHEBI:6770, SM-7338, AC1L9ALI, ICI 194,660, ...
This record was replaced with 441130.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Meropenem anhydrous


High impact information on Meropenem anhydrous


Chemical compound and disease context of Meropenem anhydrous


Biological context of Meropenem anhydrous


Anatomical context of Meropenem anhydrous


Associations of Meropenem anhydrous with other chemical compounds


Gene context of Meropenem anhydrous

  • METHODS: Colitic scid mice were treated for 1 week with antibiotics (vancomycin/meropenem) followed or not followed by a 3-week administration of Lactobacillus reuteri DSM-12246 and Lactobacillus rhamnosus 19070-2 at 2x10 live bacteria/mouse/24 hours [24].
  • When the diagnosis of FN was established, patients were started on intravenous meropenem 1 g every 8 hours and randomly assigned to receive G-CSF (5 microg/kg body weight per day subcutaneously) or not [25].
  • It is uncommon for these common bacteria, except MRSA and Stenotrophomonas maltophilia, to be resistant to meropenem in Taiwan, where a high prevalence of resistance to other antimicrobial agents was found in many of the common bacteria [26].
  • Furthermore, meropenem hypersusceptibility was obtained with a hybrid OprD porin that consisted of the PAO1 oprD gene containing loop L7 from a clinical isolate [27].
  • Increased transcription of mexB generally correlated well with meropenem resistance [28].

Analytical, diagnostic and therapeutic context of Meropenem anhydrous


  1. High-dose meropenem in meningitis due to Pseudomonas aeruginosa. Donnelly, J.P., Horrevorts, A.M., Sauerwein, R.W., De Pauw, B.E. Lancet (1992) [Pubmed]
  2. Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration. Tegeder, I., Neumann, F., Bremer, F., Brune, K., Lötsch, J., Geisslinger, G. Clin. Pharmacol. Ther. (1999) [Pubmed]
  3. Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing. Tenover, F.C., Kalsi, R.K., Williams, P.P., Carey, R.B., Stocker, S., Lonsway, D., Rasheed, J.K., Biddle, J.W., McGowan, J.E., Hanna, B. Emerging Infect. Dis. (2006) [Pubmed]
  4. Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial. Feld, R., DePauw, B., Berman, S., Keating, A., Ho, W. J. Clin. Oncol. (2000) [Pubmed]
  5. Bactericidal Activities of Meropenem and Ertapenem against Extended-Spectrum-{beta}-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae in a Neutropenic Mouse Thigh Model. Deryke, C.A., Banevicius, M.A., Fan, H.W., Nicolau, D.P. Antimicrob. Agents Chemother. (2007) [Pubmed]
  6. Effect of porins and plasmid-mediated AmpC beta-lactamases on the efficacy of beta-lactams in rat pneumonia caused by Klebsiella pneumoniae. Padilla, E., Alonso, D., Doménech-Sánchez, A., Gomez, C., Pérez, J.L., Albertí, S., Borrell, N. Antimicrob. Agents Chemother. (2006) [Pubmed]
  7. In Vitro Susceptibility of Clostridium difficile Clinical Isolates from a Multi-Institutional Outbreak in Southern Quebec, Canada. Bourgault, A.M., Lamothe, F., Loo, V.G., Poirier, L. Antimicrob. Agents Chemother. (2006) [Pubmed]
  8. Comparison of the susceptibilities of Burkholderia pseudomallei to meropenem and ceftazidime by conventional and intracellular methods. Inglis, T.J., Rodrigues, F., Rigby, P., Norton, R., Currie, B.J. Antimicrob. Agents Chemother. (2004) [Pubmed]
  9. Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections. Balfour, J.A., Bryson, H.M., Brogden, R.N. Drugs (1996) [Pubmed]
  10. In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to four fluoroquinolones (levofloxacin, d-ofloxacin, ofloxacin, and ciprofloxacin), cefpirome, and meropenem. Hoppe, J.E., Rahimi-Galougahi, E., Seibert, G. Antimicrob. Agents Chemother. (1996) [Pubmed]
  11. Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem Meningitis Study Group. Klugman, K.P., Dagan, R. Antimicrob. Agents Chemother. (1995) [Pubmed]
  12. In vitro activity of BMS-181139, a new carbapenem with potent antipseudomonal activity. Kessler, R.E., Fung-Tomc, J., Kolek, B., Minassian, B., Huczko, E., Gradelski, E., Bonner, D.P. Antimicrob. Agents Chemother. (1995) [Pubmed]
  13. High-Level Carbapenem Resistance in a Klebsiella pneumoniae Clinical Isolate Is Due to the Combination of blaACT-1 {beta}-Lactamase Production, Porin OmpK35/36 Insertional Inactivation, and Down-Regulation of the Phosphate Transport Porin PhoE. Kaczmarek, F.M., Dib-Hajj, F., Shang, W., Gootz, T.D. Antimicrob. Agents Chemother. (2006) [Pubmed]
  14. Novel acquired metallo-beta-lactamase gene, bla(SIM-1), in a class 1 integron from Acinetobacter baumannii clinical isolates from Korea. Lee, K., Yum, J.H., Yong, D., Lee, H.M., Kim, H.D., Docquier, J.D., Rossolini, G.M., Chong, Y. Antimicrob. Agents Chemother. (2005) [Pubmed]
  15. Plasmid-encoded metallo-beta-lactamase (IMP-6) conferring resistance to carbapenems, especially meropenem. Yano, H., Kuga, A., Okamoto, R., Kitasato, H., Kobayashi, T., Inoue, M. Antimicrob. Agents Chemother. (2001) [Pubmed]
  16. Meropenem clinical pharmacokinetics. Mouton, J.W., van den Anker, J.N. Clinical pharmacokinetics. (1995) [Pubmed]
  17. Postantibiotic leukocyte enhancement of meropenem against gram-positive and gram-negative strains. Novelli, A., Fallani, S., Cassetta, M.I., Conti, S., Mazzei, T. Antimicrob. Agents Chemother. (2000) [Pubmed]
  18. Meropenem pharmacokinetics and penetration into an inflammatory exudate. Wise, R., Logan, M., Cooper, M., Ashby, J.P., Andrews, J.M. Antimicrob. Agents Chemother. (1990) [Pubmed]
  19. Penetration of meropenem in lung, bronchial mucosa, and pleural tissues. Byl, B., Jacobs, F., Roucloux, I., de Franquen, P., Cappello, M., Thys, J.P. Antimicrob. Agents Chemother. (1999) [Pubmed]
  20. Penetration of meropenem into pneumonic human lung tissue as measured by in vivo microdialysis. Tomaselli, F., Maier, A., Matzi, V., Smolle-Jüttner, F.M., Dittrich, P. Antimicrob. Agents Chemother. (2004) [Pubmed]
  21. In vitro activities of the everninomicin SCH 27899 and other newer antimicrobial agents against Borrelia burgdorferi. Dever, L.L., Torigian, C.V., Barbour, A.G. Antimicrob. Agents Chemother. (1999) [Pubmed]
  22. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program. Cometta, A., Calandra, T., Gaya, H., Zinner, S.H., de Bock, R., Del Favero, A., Bucaneve, G., Crokaert, F., Kern, W.V., Klastersky, J., Langenaeken, I., Micozzi, A., Padmos, A., Paesmans, M., Viscoli, C., Glauser, M.P. Antimicrob. Agents Chemother. (1996) [Pubmed]
  23. Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis. Rodriguez-Cerrato, V., McCoig, C.C., Michelow, I.C., Ghaffar, F., Jafri, H.S., Hardy, R.D., Patel, C., Olsen, K., McCracken, G.H. Antimicrob. Agents Chemother. (2001) [Pubmed]
  24. Colitic scid mice fed Lactobacillus spp. show an ameliorated gut histopathology and an altered cytokine profile by local T cells. Møller, P.L., Paerregaard, A., Gad, M., Kristensen, N.N., Claesson, M.H. Inflamm. Bowel Dis. (2005) [Pubmed]
  25. Meropenem +/- granulocyte colony stimulating factor in the treatment of febrile neutropenic patients with cancer: prospective randomized study. Er, O., Coskun, H.S., Altinbas, M., Ozkan, M., Eser, B., Cetin, M., Altuntas, F., Unal, A. Journal of chemotherapy (Florence, Italy) (2004) [Pubmed]
  26. In vitro activity of meropenem against common pathogenic bacteria isolated in Taiwan. Chang, S.C., Fang, C.T., Chen, Y.C., Hsueh, P.R., Luh, K.T., Hsieh, W.C. Diagn. Microbiol. Infect. Dis. (1998) [Pubmed]
  27. C-terminal region of Pseudomonas aeruginosa outer membrane porin OprD modulates susceptibility to meropenem. Epp, S.F., Köhler, T., Plésiat, P., Michéa-Hamzehpour, M., Frey, J., Pechère, J.C. Antimicrob. Agents Chemother. (2001) [Pubmed]
  28. Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates. El Amin, N., Giske, C.G., Jalal, S., Keijser, B., Kronvall, G., Wretlind, B. APMIS (2005) [Pubmed]
  29. Meropenem: a review of its use in patients in intensive care. Hurst, M., Lamb, H.M. Drugs (2000) [Pubmed]
  30. Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment. Leroy, A., Fillastre, J.P., Borsa-Lebas, F., Etienne, I., Humbert, G. Antimicrob. Agents Chemother. (1992) [Pubmed]
  31. Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration. Thalhammer, F., Schenk, P., Burgmann, H., El Menyawi, I., Hollenstein, U.M., Rosenkranz, A.R., Sunder-Plassmann, G., Breyer, S., Ratheiser, K. Antimicrob. Agents Chemother. (1998) [Pubmed]
  32. Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease. Chimata, M., Nagase, M., Suzuki, Y., Shimomura, M., Kakuta, S. Antimicrob. Agents Chemother. (1993) [Pubmed]
WikiGenes - Universities